2699 ถ.ลาดพร้าว แขวงคลองเจ้าคุณสิงห์ เขตวังทองหลาง กรุงเทพฯ 10310 LADPRAO Rd. WANGYHONGLANG BANGKOK 10310

TEL: 0-2530-2244 .0-2932-2929 FAX: 0-2539-8490

e-mail ladprao@ladpraohospital.com www.ladpraohospital.com

- Translation -

Ref: LPH/SET 2020/009

May 13, 2020

Subject: Clarification on the Operating Results for the three-month period ended March 31, 2020 (Q1/2020)

То : President

The Stock Exchange of Thailand

The Board of Directors Meeting of Ladprao General Hospital Public Company Limited (the "Company"), No.2/2020, held on May 13, 2020, has approved the financial statements of the Company and its subsidiaries for the threemonth period ended March 31, 2020. The Company would like to clarify on the operating results as follows:

Revenue

For Q1/2020, total consolidated revenues advanced to Baht 424.91 million, a 9.74% or Baht 37.72 million growing up from the same period of previous year. The hospital revenues grew by 10.04% mainly due to the increase in medical service income from Social Security Office in 2020 and the continued growth of LPH medical centers. Nevertheless, the impact of the COVID 19 virus outbreak situation has resulted in some of the postponement of non-urgent or necessary access to the hospital.

In regard to the subsidiary, Asia Medical & Agricultural Laboratory and Research Center ("AMARC"), its service revenues grew by 12.60% as it provides laboratory testing and analyzing services mainly for agricultural and food products that have still been continuously necessary even amid the pandemic.

Costs and Expenses

The Company reported the consolidated costs and expenses for Q1/2020 of Baht 376.38 million, a 9.45% Grow up or Baht 32.49 million same period of previous year. respectively in resulting from upward revenues along with the expansion of branches and scopes of services serving for its growing number of customer bases.

Profit

For Q1/2020, Total consolidated net profit (attributable to owners of the Company) advanced to Baht 42.84 million, a 20.79% Grow up or Baht 7.37 million over Q1/2019

Please be informed accordingly.

Yours sincerely,

(Dr. Ungoon Chantanavich)

Chief Executive Officer

